Trial Summary
What is the purpose of this trial?
The spread of cancer to the spine is referred to as spine metastasis. Spine metastases are a common complication of cancer and are frequently associated with significant back pain. This study is being done to help improve treatment for back pain caused by spinal metastases by comparing the effectiveness of two standard treatments. These two treatments include radiation therapy (RT) alone versus radiation therapy combined with radiofrequency ablation, with or without vertebral augmentation (PVA/RFA). In addition to RT or RT with PVA/RFA, will be continued with current pain medications.
Do I have to stop taking my current medications for the trial?
No, you can continue taking your current pain medications during the trial.
What data supports the idea that Radiation + Radiofrequency Ablation for Spinal Metastases is an effective treatment?
The available research shows that Radiation + Radiofrequency Ablation is effective for treating spinal metastases. Studies highlight that advanced radiation techniques, like stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT), improve the targeting of tumors and increase the dose of radiation safely. This leads to better control of the tumor and more pain relief compared to traditional methods. For example, one study found that increasing the radiation dose resulted in more pain relief for patients. These findings suggest that this treatment can be more effective than conventional radiation therapy alone.12345
What safety data is available for radiation and radiofrequency ablation treatment for spinal metastases?
The safety data for radiation and radiofrequency ablation treatment for spinal metastases includes several studies and reports. Stereotactic body radiation therapy (SBRT) using intensity-modulated radiotherapy (IMRT) is considered safe for treating spinal bone metastasis with good tumor control and pain response. Advanced radiotherapy techniques like IMRT and image-guided radiotherapy (IGRT) have been studied for their impact on toxicity, with some reports indicating low rates of gastrointestinal and genitourinary toxicities. Image-guided radiation therapy (IGRT) has been widely adopted in clinical practice, emphasizing quality and patient safety. Additionally, studies have shown no significant association between high-dose, hypofractionated IGRT and excessive wound complications in spinal metastasis treatment.678910
Is Radiation Therapy a promising treatment for spinal metastases?
Research Team
Rupesh R Kotecha, MD
Principal Investigator
Miami Cancer Institute (MCI) at Baptist Health South Florida
Eligibility Criteria
This trial is for adults with cancer that has spread to the spine, causing significant back pain. They must have a certain level of physical ability (Zubrod Performance Status 0-3), not be pregnant, agree to use birth control if applicable, and have a specific level of back pain despite medication. Excluded are those with certain cancers like myeloma or lymphoma, non-walkers, prior radiation on the spine area, or needing immediate surgery.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Radiation Therapy (Radiation)
- Radiofrequency Ablation (RFA) (Radiation)
Radiation Therapy is already approved in Canada, Japan, China, Switzerland for the following indications:
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
- Cancer treatment
- Palliative care
- Oropharyngeal cancer
- Breast cancer
- Prostate cancer
- Lung cancer
- Brain tumors
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baptist Health South Florida
Lead Sponsor
Medtronic
Industry Sponsor
Geoff Martha
Medtronic
Chief Executive Officer since 2020
Finance degree from Penn State University
Dr. Richard Kuntz
Medtronic
Chief Medical Officer since 2023
MD, MSc